Literature DB >> 28448116

Quantitative Examination of the Active Targeting Effect: The Key Factor for Maximal Tumor Accumulation and Retention of Short-Circulated Biopolymeric Nanocarriers.

Jianquan Wang1, Gee Young Lee2, Qian Lu1, Xianghong Peng2, Jiangxiao Wu1, Siyuan Wu1, Brad A Kairdolf2, Shuming Nie1,2, Yiqing Wang1,2, Lucas A Lane1.   

Abstract

Targeted and nontargeted biopolymeric nanoparticles with identical hydrodynamic sizes and surface charges were quantitatively examined in terms of the pharmacokinetic and biodistribution differences in detail. In adding cancer cell targeting folate molecules to the surface of the heparin nanocarriers, the amount of drug delivered to the tumor is doubled, and tumor growth inhibition is significantly enhanced. The folate-targeted heparin particles offered similar therapeutic potentials compared to their synthetic long-circulating analogues, thus presenting a viable alternative for drug-delivery vehicle construction using biological polymers, which are easier for the body to eliminate.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28448116     DOI: 10.1021/acs.bioconjchem.7b00138

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  3 in total

1.  An iRGD peptide conjugated heparin nanocarrier for gastric cancer therapy.

Authors:  Shichao Ai; Shuang Zhen; Zhijian Liu; Feng Sun; Xingchen He; Feng Chu; Wenxian Guan; Jianquan Wang
Journal:  RSC Adv       Date:  2018-08-24       Impact factor: 4.036

2.  Meta-Analysis of Nanoparticle Delivery to Tumors Using a Physiologically Based Pharmacokinetic Modeling and Simulation Approach.

Authors:  Yi-Hsien Cheng; Chunla He; Jim E Riviere; Nancy A Monteiro-Riviere; Zhoumeng Lin
Journal:  ACS Nano       Date:  2020-03-04       Impact factor: 15.881

3.  Peptide Spiders: Peptide-Polymer Conjugates to Traffic Nucleic Acids.

Authors:  Ester J Kwon; Henry Ko; Sangeeta N Bhatia
Journal:  Mol Pharm       Date:  2020-07-27       Impact factor: 4.939

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.